Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study
Metrics: PDF 1127 views | HTML 1565 views | ?
Despoina Kalapanida1, Flora Zagouri1, Maria Gazouli2,3, Eleni Zografos2,3, Constantine Dimitrakakis4, Spyridon Marinopoulos4, Aris Giannos4, Theodoros N. Sergentanis1, Efstathios Kastritis1, Evangelos Terpos1 and Meletios-Athanasios Dimopoulos1
1Department of Clinical Therapeutics, Alexandra Hospital, Medical School, University of Athens, Athens, Greece
2Department of Basic Medical Sciences, Laboratory of Biology, University of Athens School of Medicine, Athens, Greece
3Laboratory of Cell and Gene Therapy, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
4Department of Obstetrics and Gynaecology, Alexandra Hospital, Medical school, University of Athens, Athens, Greece
Flora Zagouri, email: [email protected]
Keywords: SNPs; pre-miR-34a; miRNA; triple negative breast cancer; biomarker
Received: September 13, 2018 Accepted: November 03, 2018 Published: December 11, 2018
Aim: The purpose of this study is to evaluate the role of pre-miR34a rs72631823 as potential risk factor and/or prognostic marker in patients with triple negative breast cancer.
Methods: 114 samples of DNA from paraffin embedded breast normal tissues of patients with triple negative breast cancer and 124 samples of healthy controls were collected and analyzed for pre-miR34a rs72631823 polymorphism.
Results: Pre-miR34a rs72631823 A allele was associated with increased TNBC risk both in univariate and multivariate analysis. The number of pre-miR34a rs72631823 AA subjects was very small and the association did not reach significance (p = 0.176, Fisher’s exact test). The examined polymorphism was not associated with overall survival at the univariate or multivariate Cox regression analysis (adjusted HR = 1.60, 95%CI: 0.64–3.96 for miR34 rs72631823 GA/AA vs. GG).
Conclusion: Our case-control study suggests that pre-miR34a rs72631823 A allele is associated with increased triple negative breast cancer risk.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.